According to a new press release, “Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and Signals Analytics, the next generation advanced analytics platform that leverages external data to uncover trends and novel insights, today announced a joint offering that helps life sciences companies to identify new opportunities, mitigate investment risks and accelerate the drug development process. The combined solution leverages Signals Analytics’ AI-engines with Informa Pharma Intelligence’s industry leading R&D and commercial intelligence services to provide customers with timely, relevant and complete insights. Informa Pharma Intelligence will utilize their best-in-class content and Signals Analytics’ powerful deep learning technology approach to launch three new Apps focused on supporting earlier stage evaluation and prioritization. The Apps created will provide life sciences companies with a 360-degree market view, configured with smart contextual engines to drive actionable business decisions.”
The release goes on, “The solution includes the following Apps: (1) Target Prioritization: Using Pharma Intelligence databases such as Pharmaprojects, Trialtrove and Biomedtracker as well as public forums, the App will evaluate molecular development by stage, therapeutic potential and the competitive landscape. In turn, users will have access to a comprehensive library of insights that evaluate the commercial success and risk factors of an asset. (2) Modality Innovation: Utilizing a harmonized and comprehensive combination of public sources and Pharma Intelligence’s leading databases, this App provides an analysis from the perspective of the individual modality and provides a maturity score. In turn, users can establish which modalities should be prioritized when investigating trending technology solutions. (3) Competitive Benchmarking: Key insights are derived here around how organizations benchmark against one another relative to drugs, trials, events, patents and more. In turn, users can gain an overview of competitor’s medical condition pipeline, which target molecules, and what modalities they are working on.”
Read more at Globe Newswire.
Image used under license from Shutterstock.com